Helix BioPharma (TSE: HBP) CEO Dr Heman Chao sat down with Steve Darling from Proactive in New York to share details they have just completed a fundraise. Chao also talked about his desire to uplist the company to the Nasdaq.
Dr Chao also told Proactive what is planned this year in the development of their L-DOS47 cancer drug.
Price: 1.35 CAD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Helix BioPharma Corp. named herein, including the promotion by the Company of Helix BioPharma Corp. in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE
NexTech AR Solutions (CSE:NTAR-OTCQB: NEXCF) CEO Evan Gappelberg joined Steve Darling from Proactive Vancouver with news the company has signed another deal with a company in the arms sector. This deal is with Steyr Arms, a world-renowned firearms manufacturer. Gappelberg says NexTech...
Finance
